Advances in protein phosphorylation analysis by mass spectrometry (MS) are enabling the generation of high quality, quantitative datasets of protein phosphorylation with a breadth of coverage and reproducibility not previously attainable. Comparisons of signaling responses in cells at a network level are now feasible and studies looking at cellular response to ligand stimulation, drug treatment or genetic modification are transforming our understanding of how cellular decision processes are encoded through the signaling network. The large and dynamic datasets acquired through MS-based phosphoproteomics can be combined with other types of biological data for computational modeling of cellular decision processes with direct biological relevance to cellular state and predictive of cellular response. Signaling analysis at a network level is just beginning. Challenges remain in validating and translating initial models generated using defined in vitro models to in vivo systems. The advent of higher throughput methods for validating models generated with MS will deepen our understanding of the relationship between signaling and disease and therefore the development and implementation of therapeutics.
INTRODUCTION
Reversible protein phosphorylation regulates many aspects of cellular physiology, mediating proteinprotein interactions, sub-cellular localization and the activity states of many cellular enzymes [1, 2] . It is a central biochemical mechanism by which cells maintain homeostasis in response to changing environmental conditions and functionally adjust to new circumstances. Cellular information flow, initiated by receptors at the cell membrane in response to external stimuli, is transmitted by cascades of protein phosphorylation throughout the cell membrane and cytoplasm, modifying aspects of cellular morphology and organization at a physical level and arriving at the nucleus via transcription factors to mediate gene expression. Although often represented as being a series of pathways generally running in parallel, protein phosphorylation cascades more likely represent routes of information flow through a complex network of signaling molecules, transmitting information across canonical pathways and throughout the cellular system.
PROTEIN PHOSPHORYLATION AND SIGNAL TRANSDUCTION IN DISEASE
The central importance of protein phosphorylation in signal transduction is readily recognized by the prominent role protein phosphorylation plays in disease, particularly diabetes, inflammation and cancer [3] [4] [5] [6] . For example, in cancer, several consistent disease traits have been defined: unlimited replicative capability, self-sufficiency in pro-growth factors, independence from anti-growth factors, evasion of programmed cell death, invasive and migratory behavior in establishing new sites (metastasis), and promotion of vascular growth in proximal normal tissue, providing essential nutrient support [7] . Each of these common traits of cancer is regulated by complex networks of protein phosphorylation mediated by protein kinases and phosphatases, resulting in integrated information flow controlling cellular behavior [8] . Protein kinases catalyze the individual enzymatic steps in protein phosphorylation cascades and have thus become a major therapeutic target for drug development in an effort to block or redirect information flow important for initiating and maintaining these disease traits.
FUNCTIONAL ASSESSMENT OF SIGNAL TRANSDUCTION
With the advent of comprehensive genomic information, DNA expression microarrays, yeast twohybrid technology and mass spectrometry (MS)-based proteomic analysis, the generation of large-scale static maps of protein interactions which define the potential structure of signaling networks are available [9, 10] . Network architecture alone, however, is insufficient to understand how complex pathway dynamics integrate numerous inputs to drive information transfer and ultimately cellular decisions [11] . Cell signaling and the output derived through common effector molecules are governed not just by structure, but by spatial and temporal dynamics which define important characteristics of signaling, such as gradient flow, oscillatory behavior and bi-stability [12] . The dynamic characteristics of a signaling network, though complex, can be captured given the capability to quantitatively measure signaling events temporally. One systems-level approach is to generate multiple conditions for perturbing signaling combined with multi-parameter measurement of relevant signaling events, in a cue-signal-response experimental design, providing high-dimensional datasets for analysis [13] [14] [15] [16] . Initial studies using this data-driven approach have relied on large sets of parameters defined for a small number of pre-defined signaling molecules, based upon prior knowledge. Thus, a relatively limited region of signaling space has been sampled in these studies.
In clinical development of therapeutic compounds, identification of biomarkers of drug action is necessary to speed clinical trials and improve success through appropriate patient stratification. Many companies have initiated pharmacogenomic programs to identify genetic or gene expression signatures associated with sensitivity to drug treatment to identify patients who have a higher likelihood of response to therapy. However, for Tarceva (erlotinib) and Iressa (gefitinib), kinase inhibitors targeting ErbB1 (epidermal growth factor [EGF] receptor, EGFR), clinical experience demonstrated that gene over-expression of ErbB1 did not correlate with sensitivity to treatment. For both molecules, the best class of responders had activating mutations in ErbB1 and for Iressa, importantly, downstream functional activation of Akt through phosphorylation [17] [18] [19] . This suggests that functional information on phosphorylation and therefore signaling state, even though limited in scope, can be most informative.
The ability to sample large portions of signaling space is of particular importance given that activation of multiple receptors often occurs simultaneously. In recent studies, on glioblastoma for example, cultured glioblastoma cell lines demonstrated co-activation of receptors not activated through direct ligand stimulation. In addition, xenograft models of the same cell lines demonstrated different receptor co-activation patterns compared to the same cells in culture. The patterns of receptor activation obtained using cultured glioblastoma cell lines also differed significantly from that observed in primary glioblastoma tumors. Thus, multiple different receptors can be activated in the same tumor type depending on the individual tumor and environmental conditions. Downstream signaling as a function of multiple receptor tyrosine kinase (RTK) activation was explored for a limited set of signaling targets, but the consequences and functional relevance of multiple receptor activation, other than lack of sensitivity to single RTK inhibitors in growth inhibition assays, remains to be fully explored [20] . These studies and others indicate that functional analysis of protein phosphorylation on a large scale should be highly informative for understanding cellular decision processes and to identify biomarkers for disease and therapeutic efficacy.
PHOSPHOPROTEOMICS FOR SAMPLING REGIONS OF SIGNALING SPACE
The main impediment to undertaking a systemslevel approach to cellular signaling is the inability to generate large-scale quantitative phosphorylation data. Recent advances in MS enabling quantitative analysis of changes in protein phosphorylation are overcoming this hurdle, particularly in the measurement of tyrosine phosphorylation. Although tyrosine phosphorylation represents a small portion (<1%) of overall protein phosphorylation, RTKs play particularly important roles in regulating aspects of cellular behavior and physiology, such as proliferation, cell cycle progression, metabolism, differentiation, survival and migration [21] [22] [23] . This is especially true in diseases such as cancer, where mutations in RTK genes contribute significantly to pathway activation and subsequent disease behavior. However, it is also clear that multiple mutations enable oncogenic behavior, with either loss-of-function (tumor suppressors) or gain-of-function (oncogenes) mutations in downstream effectors, so functional assessment must extend beyond the receptor level [24, 25] . One drawback of selectively monitoring phosphotyrosine is that important regulation of the network response by other modifications such as phosphoserine and phosphothreonine are not directly measured. Analysis of tyrosine phosphorylation however, strikes an appropriate balance between relevance to disease and information content through sampling a breadth of signaling space with sufficient data density and throughput to generate meaningful and reproducible datasets. Moreover, the identification of important signaling nodes is achieved in a data-driven discovery manner through MS, rather than from preconceived notions of functional importance and still captures important regulatory information through assessment of the functional state of the network.
QUANTITATIVE PHOSPHOPROTEOMICSçTHE IMPORTANCE OF SAMPLE PREPARATION
Interrogation of cell signaling networks via MS provides a number of advantages for systems-level analysis, including broad coverage of phosphorylation sites measured in a single experiment, sitespecific identification of modifications, the ability to quantify changes in phosphorylation, and unbiased acquisition of data leading to the discovery of new and important phosphorylation events. For signaling studies, it is beneficial to begin with cell lysis and full denaturation of the sample using strong urea-based buffers amenable to downstream processing as this allows for accurate temporal analysis, providing sample stability as phosphorylation states are essentially frozen at the point of cell lysis. Phosphatase and kinase activities are effectively nullified without the need for complex phosphatase inhibitor cocktails. Denatured proteins are then reduced and alkylated at cysteine residues prior to digestion, to ensure that peptide precursors introduced to the mass spectrometer represent continuous linear amino acid sequences that are readily searchable in databases derived from genomic information (Figure 1 ). Protein digestion is typically carried out with sequencing grade trypsin, though it has been shown that using other proteases such as Lys-C can provide additional and differential sequence coverage when both enzymes are used on replicate samples [26] . However, in contexts where capturing information related to sub-cellular localization is important for instance, other lysis strategies must be employed to retain the ability to separate organelles before full denaturation is achieved. Greater care must be taken in these cases to maintain the integrity of phosphorylation in the sample, but the additional spatial information can be useful [27] .
A crucial step for successful phosphoproteomic analysis by MS is to specifically enrich and concentrate phosphopeptides prior to the analysis. Decreasing sample complexity results in a higher likelihood of sampling relevant sequences, as phosphorylated peptides represent a significant minority of the overall peptide pool. Abundant unphosphorylated peptides can suppress ionization of phosphopeptides, further decreasing the likelihood of sampling sequences of interest during MS analysis. For phosphotyrosine analysis, immunoaffinity-based enrichment strategies have been effective in reducing sample complexity, providing a facile means of concentrating phosphospeptides for in-line chromatography separations and introduction by electrospray sources for MS analysis [28, 29] . Phosphopeptide capture is more complete and efficient when an excess amount of antibody is used in the enrichment step. Unfortunately, excess antibody can lead to significant non-specific binding in addition to the desired phosphopeptide capture, with upwards of 90% of the immunoprecipitation eluate being unphosphorylated (unpublished observation). To overcome this problem, additional enrichment of phosphopeptides by immobilized metal affinity chromatography (IMAC) can be implemented following phosphopeptide immunoprecipitation. IMAC approaches utilizing iron as the phosphate binding agent have served as the gold standard for enrichment in many phosphoproteomic-MS studies, but recently titanium dioxide-based IMAC has emerged for enrichment of phosphorylated peptides [30, 31] . The combined strategy of immunoaffinity and IMAC enrichment has worked exceptionally well for analysis of phosphotyrosines [29] . In the case of the abundant phosphothreonine and phosphoserine peptide populations there are no useful panphosphoserine or threonine antibodies, and therefore a broad dual enrichment strategy for these classes of phosphopeptides is not currently feasible. However, multiple options are available for enrichment and analysis of serine-and threonine-phosphorylated peptides in the context of global phosphoproteomics and have been the subject of other reviews [32] [33] [34] . Recent notable studies have significantly increased coverage of the phosphoproteome with thousands of phosphosites measured in nuclear extracts, mouse liver and in evaluating the temporal dynamics of EGFR pathway signaling [22, 35, 36] . These and related studies have contributed a significant number of novel phosphorylation sites, but are typically limited to analyses focused on cataloging, clustering and bioinformatic mining. Quantitative comparisons across multiple different conditions utilizing these methods can be unwieldy. As discussed below, higher level mechanistic signaling analyses relating signaling events to phenotypic outcomes focus on specific pathways or other subsets for sampling overall signaling space, readily accommodating quantitative comparisons. It should be noted that truly comprehensive coverage of the phosphoproteome will ultimately rely on a number of complementary analytical approaches, as limitations in MS make detection of some proteolytic fragments unfeasible.
QUANTITATIVE ASSESSMENT OF PROTEIN PHOSPHORYLATION BY MS
While it is desirable to achieve as broad coverage of phosphopeptides as possible in MS analyses, sitespecific quantitative data are far more informative when levels of phosphorylation can be compared across biological conditions and time points, but Pooled analysis workflow where enrichment for phosphorylated peptides is performed (either on-line or off-line), followed by concentration on Fe3 þ loaded IMAC, with introduction to MS via a nano-flow electrospray interface. MS/MS analysis is performed using intelligent data acquisition (IDA) followed by sequence analysis and search. (C) Data analysis using two different protein search engines for hit cross-validation identifies protein by sequence and sites of modification. Quantification of iTRAQ Õ labeling is performed on confirmed hits, followed and comparison of biological replicate data and mapping to biological pathways.
requires highly reproducible analyses. Isobaric mass tags, such as iTRAQ Õ (Applied Biosystems, Foster City, CA) labels, provide distinct advantages in such quantitative analyses [37] . Currently, four (or eight) stable isotope mass labels, which covalently react with free amino groups of peptides and lysine side chains after digestion and clean-up of lysates, are available. These reagents are isotopically balanced around a cleavable bond such that when intact, they have the same overall mass, but yield unique reporter ions after MS/MS fragmentation. In the analysis, each biological condition can be labeled with a different mass tag, and then samples are combined and enriched for phosphopeptides. During acquisition of tandem mass spectra, each fragmentation of a selected precursor ion generates iTRAQ Õ reporter ions, spaced by one Dalton between 114 and 117 m/z (with additional masses at 113, 118, 119, and 121 for the 8-plex). The areas of these peaks can be integrated and compared to each other, providing quantitative ratios of peptide levels between the different conditions. iTRAQ Õ -based stable isotope quantification provides some advantages over other MS quantitation strategies. For instance, the same peptide from each condition will co-elute in the full scan mass spectrum, increasing the total intensity of each phosphopeptide and in turn the likelihood for selection and fragmentation in data-dependent acquisition mode. Also, labeling with 8-plex iTRAQ Õ -based stable isotope incorporation makes comparison of signaling at multiple time points or conditions possible, although the 8-plex can increase complexity and enhance ion suppression. This approach, however, far exceeds the throughput on a per sample basis available with SILAC TM (Invitrogen, Carlsbad, CA) or AQUA TM (Sigma-Aldrich, St. Louis, MO)-based labeling analyses [38] [39] [40] . AQUA TM quantitation strategies cannot directly compare multiple conditions within a single MS analysis and requires custom peptide synthesis in order to quantify peptides of interest, whereas iTRAQ Õ mass tags label all peptides in a lysate. While SILAC TM strategies can compare conditions, the need for labeling during cell culture limits this approach. Since iTRAQ Õ labeling of peptides is performed after lysis and digestion, it is not limited to cell culture, and can be applied to in vivo tissue or tumor samples [41, 42] . Additionally, both quantitation and sequence identification are performed from the same product ion spectra, giving less error in relative quantitation and easier validation. iTRAQ Õ quantitation is highly reproducible when properly validated, with global CVs between biological replicates on par with many accepted immunoassay formats (typically <20% CV, Figure 2 ). As a result, a common replicate sample can be included as an internal control with two different labeled experimental samples or more, making combination of datasets facile and less error prone. For temporal resolution, dose response at multiple concentrations, comparisons of multiple unique compounds (Figure 3 ), or studies of multiple genetic mutants/ disease models, this approach enables robust comparisons in signaling response for studying the mechanism of action of a compound or for identifying attractive therapeutic targets for a given pathology. Analysis by iTRAQ Õ labeling does introduce some limitations to the design of MS experiments. While other approaches offer quantitative information directly in the MS survey scan, allowing simultaneous sampling of tens to hundreds of peptides, iTRAQ Õ quantitation requires selection of a precursor ion and MS/MS fragmentation. This significantly decreases sampling throughput and requires that sample complexity be reduced before MS analysis. iTRAQ Õ labeling can be limiting and potentially cost prohibitive when labeling samples abundant in total protein, affecting analyses where more cell material is required to meet sensitivity demands of detecting low-level targets of interest. A contaminant ion at 116.07 Da can also contribute to the 116.1 Da iTRAQ Õ reporter peak area if a mass spectrometer with insufficient mass resolution is used for the analysis and the two peak areas cannot be resolved [43] . This contamination can bias relative comparisons if careful manual validation and correction is not performed. Careful tuning of mass spectrometer resolution in initial gating and selection, as well as for achieving the required time of flight detector resolution for the contaminant issues discussed above, is crucial to achieve reliable iTRAQ Õ quantitation. Higher molecular mass isobaric tags (ExacTag Õ , Perkin-Elmer, Waltham, MA) are also available for increased sample multiplexing and have found utility with conventional ion trap mass spectrometers. However, the higher mass of these tags may reduce ionization efficiency of some phosphopeptides. In addition, the higher mass detection range potentially results in increased contribution by contaminant fragment ions, compared with the lower mass iTRAQ Õ tags, due to increased spectral background in the higher mass range.
SIGNALING SPACE AND QUANTITATIVE ASSESSMENTçLEADING TO FUNCTIONAL BIOLOGY
Combined phosphopeptide enrichment and quantitative labeling techniques have been successfully used in a number of applications. Labeling with iTRAQ Õ mass tags and phosphotyrosine enrichment was employed to study EGF-mediated signaling temporally, in human mammary epithelial cells (HMEC) using both data-dependent acquisition and multiple reaction monitoring MS strategies [29, 43] . By combining two sets of 4-plex iTRAQ Õ data with one time point in common, a 7-point time course was constructed to examine signaling at early and late times after stimulation with EGF, thereby highlighting the importance of monitoring signaling events in a dynamic fashion. The time-resolved quantitation of tyrosine phosphorylation and analysis by self-organizing maps identified modules of phosphorylation events associated with receptorinitiated signal transduction, endocytosis, trafficking and regulation. In a related study, different signaling cues resulting from over-expression of the HER2 receptor were compared via iTRAQ Õ labeling and the phosphotyrosine signaling space across these conditions was used to correlate the effect of stimulation and receptor levels on cell behavior in the context of cancer-related phenotypes [44, 45] . The experimental cue-signal-response design enabled a modeling framework using multi-parameter measurement of relevant signaling events for generating a high-dimensional dataset, only this time in a discovery-mode wherein relevant signaling targets were not determined in advance as in the more limited studies cited previously. One of the key results of this study was that determinants of phenotypic response in the signaling network were not the usual suspects and not obvious, defining a new set of relevant changes in signaling that represented a 'network gauge' of cell state. This approach has also been applied to the study of mutant EGFR receptor levels important in glioblastoma progression to assess differences in signaling pathway utilization [46] . By attaining broader quantitative coverage of signaling pathways via MS, the authors were able to predict and successfully confirm co-activation of the c-MET receptor in the presence of EGFRvIII and that a combination of kinase inhibitors targeting c-MET and EGFRvIII receptors would have a synergistic effect in killing tumor cells. Moreover, the data supported the efficacy of this combination even in the absence of PTEN function, a common mutated tumor suppressor found in a high percentage of gliomas.
HIGHER LEVEL ANALYSIS OF PHOSPHOPROTEOMIC DATAçMAKING THE CONNECTION
While these and other strategies employing phosphoenrichment and site-specific quantitation by labeling and MS analysis can offer immediate utility by revealing novel targets or signaling pathway utilization, it is challenging to fully interpret the quantity and complexity of data without higher level analysis. Increased coverage aside, de-convoluting temporal and concentration dependent effects over multiple signaling pathways is a daunting task and crude observation alone can often lead to spurious conclusions. Employing various approaches in computational modeling can aid in elucidating key targets, and reveal compound mechanism and correlation of perturbations in cell signaling networks to cell or tissue phenotype. This knowledge can aid in target selection as well as directing chemistry efforts to achieve improvement in dose-dependent compound activity.
There is no single modeling approach that should be exclusively applied to proteomic data, and the high degree of dimensionality in MS-based phosphoproteomic datasets can create issues in building accurate models [15, 47] . Models and modeling approaches are continually evolving to face these issues, as throughput and coverage in proteomic data improve with further advances in MS technology, sequence identification and peptide quantitation methods. In general, large quantitative phosphotyrosine datasets are well suited for a number of approaches, especially when complemented with other types of data [48, 49] . Figure 4 illustrates common strategies taken to couple proteomic data with computational modeling approaches, linking model outputs with biological phenotype data and validation.
The two most obvious applications for these datasets are network focused and end function/ phenotype focused. With increasingly broad coverage of the tyrosine signaling network overall, statistical approaches and clustering methods can be used to infer novel pathway structure and involvement of various sites and proteins in information flow from a given cue. Causal relationships can be inferred from experimental data to determine overall protein network structure [50] [51] [52] or common expression patterns can be grouped using selforganizing map routines or other algorithms [29, 53] . These approaches also aid in visualizing data for postulating mechanistic involvement of proteins within signaling pathways. With quantitative temporal datasets, refined network structures can be used to build informative deterministic models with predictive ability for information flow and signaling response outputs. Accurate parameter estimation is paramount in developing informative deterministic models, and MS analyses with increased temporal resolution should aid these efforts. With accurate deterministic models, predictions can be made on the optimal targets for a desired therapeutic signaling output, and with adequate model coverage, avoid unwanted off-target effects or perturbation of pathways other than the pathway being primarily targeted.
Statistical methods can also be useful especially when signaling data are coupled with phenotypic outputs. Partial least squares regression and principal component analyses can reveal key signaling nodes that correlate strongly with a phenotype of interest [15, 44] . These approaches do not require prior knowledge of network structure and along with selforganizing map algorithms can provide a rapid means of extracting interesting targets or pathway clusters from complex datasets. By examining how signaling nodes spatially cluster on a newly defined orthogonal set of principal components, significant data reduction is achieved, allowing determination of the proximity of a limited number of specific phosphorylation sites to biologically relevant phenotypic states ( Figure 5 ). Beyond interesting target identification, these analyses can also be fed back to mechanistic hypothesis generation and follow-up.
In many of these modeling approaches, the accuracy of a given model is dependent on the quality and breadth of data upon which it was trained. The ability to quantitatively compare multiple samples within a MS analysis can be beneficial to this end, as multiple signaling cues and perturbations can be examined in parallel and used to expand model signal space. Additionally, models and modeling outputs, as well as MS data itself, must be carefully validated, and with the increased data content of current MS approaches, it is clear that new tools are needed for more efficient follow-up Figure 4 : Overview for integrating biological experiments, cell signaling data from MS analyses, and canonical pathway knowledge (A^C) with computational modeling approaches to achieve different biological goals (D^F). Experiments measuring phenotypic outputs of a cell or tissue model (A) and quantitative changes in phosphorylation measured by MS are used to build detailed large scale networks of signaling events across different cells, tissues, treatment conditions or time points (B). Statistical analysis of data is used to identify significant differences between datasets revealing interesting changes in phosphorylation sites, which are then mapped by quantitative phosphorylation levels to known signaling pathways (C). Integrated outputs from these analyses drive deterministic, probabilistic and statistical models for higher level analysis with reference to different biologically driven analytical goals. Deterministic models, defined by pathway mapping and quantitative MS analysis, allow simulation of signaling outcomes, with sensitivity analyses to identify important nodes and pathway steps (D). Often, quantitative MS data can be used alone to determine network architecture, find new pathway interactions, or group phosphorylation sites by common temporal or dose dependent expression patterns (E).This information is fed back to refine more accurate and predictive deterministic models. Finally MS data can be combined with phenotypic outputs to determine statistical relationships between signaling events and cell decisions, providing additional insight into key therapeutic targets (F). Combined experimental design, data acquisition and modeling efforts are an iterative process, whereupon results obtained initially inform upon the next set of experiments and analyses to refine models and validate new predictions, with the goal of continually increasing the understanding of important signaling events and their relationship to cell decision processes.
and biological validation. It has been demonstrated that model reliability and validation benefits from training and testing models with data from multiple experimental techniques [54] . MS data alone should not be counted on to solely drive model generation and validation. When coupled with other analyses, for example RNA expression, or antibody-based immunoassay data, MS generated phosphoproteomic analysis for generating new hypotheses and experimental direction is an especially powerful approach.
FUTURE DIRECTIONS
There are many challenges which remain to be addressed in systems approaches to signaling networks and their relation to understanding disease and therapeutic selection for treatment. In order to identify the important integrators of signaling networks, efforts have focused on cell culture models and cue-signal-response designs to stimulate the network by pre-defined mechanisms, elucidating information flow within the system. To more fully cover the communication network in a given cellular system, multiple cues are needed to define cross-talk, feedback mechanisms and other regulatory mechanisms which channel information flow. In addition, the question as to how common these 'network gauge' nodes are across different cellular systems remains unclear. There is preliminary evidence that the 'network gauge' can translate across cellular systems, via common effector mechanisms, but this has not been fully explored yet [25] . Moreover, in translating these cell culture experimental designs to in vivo systems, the disease biology will certainly be different compared to culture models due to the complex nature of the in vivo environment. Experimental interrogation of in vivo models using MS-based methods can address this uncertainty and determine if the common effector mechanisms remain relevant. The methodologies described above utilizing iTRAQ Õ labeling and improved sensitivity due to both instrumentation advances and up-front sample processing make many in vivo models, as well as human samples, accessible for phosphoproteomic analysis by MS. In vivo models are not cue-signal-response models, however, and it is not yet clear how steady-state measurements can be integrated into the cue-signal-response dynamic models built from cell culture.
Bridging the gap between dynamic cell-based systems and steady-state in vivo samples might be achieved by experimental designs which incorporate compound treatment in a chemical biology driven approach. Specific molecules with narrow biochemical specificity can inhibit a particular kinase or small subset of kinases, and the effect on the information flow can be assessed using MS-based phosphoproteomics in cell culture. The same small molecule kinase inhibitors, given adequate exposure data to support compound activity in vivo, can then be used as perturbations of in vivo model systems. By application of these compounds in cell culture models and in vivo animal models, common effectors for biological function can be identified, providing an essential functional bridge between in vitro and in vivo models, potentially with future applicability to human tumors. Specificity of kinase inhibitors have been investigated extensively [55, 56] . Recently, using phage expression of kinases and a competitive binding approach, compounds have been extensively profiled against a large number of kinases, representing both on-target and off-target effects. The ability to define specificity through doserelated effects in these screens provides insight into mapping inhibitor specificity onto the kinome [57, 58] . In addition, MS analysis and quantitative iTRAQ Õ labeling was recently employed in a novel strategy to monitor kinase inhibitor activity [59] . By performing a competitive binding assay with kinase inhibitor beads and combining the labeled bead eluates for quantitative comparison, activity of a number of compounds was profiled and novel targets were discovered for a clinically relevant compound.
Although many of the most specific small molecule kinase inhibitors might not be useful from the clinical perspective, they are excellent tools for probing existing signaling networks in vivo. Several examples of using specific single compounds to probe the role of the target and pathways in a variety of tumor models have been performed [60] . Broader screening approaches have also used chemical biology to characterize genotype and phenotype in cell lines, establishing correlations with response to specific compound treatment [61] . Given the ability of MS-based phosphoproteomic analysis to look at network-level signaling, the combination of chemical biology with a systems-level analysis of cellular signaling appears propitious.
Monotherapy with a single specific kinase inhibitor has demonstrated efficacy in only a subfraction of human tumors. Even with patient selection for target expression, targeted therapies result in very limited response rates in most solid tumors [17, 18, 61] . Target validation in vivo is therefore one of the main hurdles facing the design, development and clinical use of new targeted therapeutics. Currently, the ability to predict efficacy of treatment is limited by our understanding of signaling and tumor genetics. Determination of key nodes using cue-signal-response models enables critical assessment of target validation, as the correlation of specific target inhibition with phenotype, predicted by the state of 'network gauge' nodes, could be determined prior to in vivo experiments. Monitoring the state of key network nodes in addition to direct target inhibition in vivo can potentially overcome the disconnect in target validation when moving from in vitro models to in vivo models and eventually to the validation of clinical hypotheses for the treatment of human disease.
It has also become increasingly clear that single targeted therapy in most solid tumors will not be sufficient to achieve significant positive therapeutic outcome. In several systems, it has been shown that multiple RTKs can be activated in a given tumor, and from the network perspective, downstream effectors have significant influence on how these multiple signals are integrated to result in cellular decisions. A common practice in oncology is combination therapy to achieve efficacy. Currently, this usually means combining a targeted therapy with traditional chemotherapeutic regimens. In the future, signaling network analysis will be able to determine which targeted therapies can be combined in a rational manner to achieve the desired outcome.
Unlike gene expression analysis or genetic mutational analysis, signaling analysis reflects the site of drug action itself, within the current context of the cellular state. The combination of information flow analysis of signaling with proximity to the site of drug action enables the key points of intervention to be determined directly. This provides the ability to choose which sets of inhibitors in combination may block the integrated information flow in the network leading to disease characteristics such as increased cell proliferation or metastatic behavior.
The ability to validate models derived from discovery MS efforts will necessarily need to rely upon other methods as the throughput needed for full validation, and therefore the concepts outlined above, require larger numbers of test samples than can readily be accommodated by MS methodologies. Model validation has been traditionally accomplished using higher throughput immunoassays. However, traditional protein-based assays for phosphorylation analysis lack both site specificity and absolute quantification as the ability to generate phosphorylated protein standards is problematic. In addition, the simultaneous measurement of multiple phosphorylation events with protein-based immunoassays is difficult due to reagent cross-reactivity, the complexity of multiplexing numerous detection antibodies and finding specific reagents with suitable sensitivity and dynamic range [62] . Other assay technologies such as reverse microarrays, although easy to enable, sensitive and compatible with multiplex analysis, lack both the specificity and quantification to provide robust data for advanced modeling and comparison to MS-based discovery data. Advances in assay platforms for the analysis of signaling are emerging which address the complexity of multiplex assay development while enabling protein specificity, phosphorylation sitespecificity, quantification, and sample throughput requirements for full validation of signaling models, based upon MS discovery data [63, 64] . In the near future, as MS discovery-based sites of importance for cellular decisions are revealed and models are trained on this data, rigorous testing of models powered by improved sample throughput will be possible. Systematic analysis of signaling and its relationship to disease will then be at the forefront of both drug discovery and individualized patient assessment for choosing the best therapeutic option.
Key Points
Cellular response through signal transduction comprises a complex network of dynamic changes in protein phosphorylation. MS methods to quantitatively measure protein phosphorylation are enabling a breadth of coverage and reproducibility not previously attainable. Monitoring changes in tyrosine phosphorylation is a useful and robust approach for sampling large regions of signaling space. Combining different types of biological data with quantitative dynamic phosphorylation data, initial computational models can be generated which are predictive of cellular response, and iterated upon for data reduction and refinement, suggesting new experimental hypotheses and direction. Challenges remain in the validation and translation of these models from in vitro to in vivo systems, but are likely to be addressed by new immunoassay technologies for quantifying changes in protein phosphorylation in high-density formats.
